ARQULE – Failure in NSCLC – Disappointing but Not “The End” for Tivantinib

Date: 2015-07

Early discontinuation following a planned interim analysis of the PhIII global MARQUEE trial of Tivantinib (formerly ARQ-197, c-MET inhibitor, partnered with Daiichi Sankyo – DS for worldwide except Asia), recommended by the independent Data Monitoring Committee (DMC) and suspension of Asia-based PhIII trial (ATTENTION) by ARQL’s Asian partner, Kyowa Hakko Kirin (KHK) on the recommendation of Japanese regulators after reports of suspected cases of Interstitial Lung Disease (ILD) were major setbacks. After these setbacks, investors may write-off ARQL, but based on positive PhII data in 2nd- line HepatoCellular Carcinoma (HCC)… For further detail, please read our report released on 2nd October, 2012 on ARQL, titled “Failure in NSCLC – Disappointing but Not “The End” for Tivantinib”.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample